CN113372415A - Human bladder cancer specific antigen binding peptide - Google Patents
Human bladder cancer specific antigen binding peptide Download PDFInfo
- Publication number
- CN113372415A CN113372415A CN202010560431.9A CN202010560431A CN113372415A CN 113372415 A CN113372415 A CN 113372415A CN 202010560431 A CN202010560431 A CN 202010560431A CN 113372415 A CN113372415 A CN 113372415A
- Authority
- CN
- China
- Prior art keywords
- bladder cancer
- residue
- binding peptide
- specific antigen
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4742—Keratin; Cytokeratin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A human bladder cancer specific antigen binding peptide belongs to the field of biological medicine, and is characterized in that: the human bladder cancer specific antigen binding peptide consists of 12 amino acids, the amino acid sequence is MPMFKHRMFHTH, wherein M is methionine residue, P is proline residue, F is phenylalanine residue, K is lysine residue, H is histidine residue, R is arginine residue, and T is threonine residue. Has a molecular weight of 2024.0, and can specifically bind to bladder cancer antigen in human urine. The beneficial effects are that: the polypeptide fragment and the derivative thereof have important application values in early diagnosis, screening and targeted therapy of bladder cancer tumors. Compared with the traditional screening method, the method has the advantages of simple and convenient operation by applying the phage display technology, easy realization of large-scale production, and laying a foundation for targeted development and targeted drug selection due to the advantages of small relative molecular weight, weak immunogenicity, high activity and the like.
Description
Technical Field
The invention belongs to the field of biological medicines, and relates to improvement of screening and identification of a human bladder cancer specific antigen-binding peptide.
Background
Bladder cancer refers to malignant tumor occurring on the mucous membrane of the bladder, is the most common malignant tumor of the urinary system, is one of ten common tumors of the whole body, accounts for the first place of the incidence rate of the genitourinary tumor in China, and has the incidence rate second to prostate cancer in western countries, which is 2 nd. Bladder cancer is considered to be a highly immunogenic type of cancer with a higher mutation rate than other types of cancer. Since the time of diagnosis directly affects the survival of the patient, early detection and lifelong monitoring of bladder cancer is very important.
Preliminary diagnostic tests for bladder cancer typically include cystoscopy and urine cytology. Cystoscopy is a gold standard for early diagnosis and staging of bladder cancer. If a bladder lump is found, transurethral cystotomy (TURBT) is performed. Excised bladder tumor specimens should include muscle to adequately assess the depth of tumor infiltration. If Carcinoma In Situ (CIS) is found, multiple random biopsies, including several different regions of the bladder and prostatic urethra, may be required to assess the extent of tumor distribution.
The urothelial cancer tissue is excised or biopsied, the tumors are graded according to their microscopic morphology, and the depth of infiltration of the tumors is assessed. Tumors are classified as low-grade or high-grade, and the diagnostic system relies on the degree of atypia, hypertrophy of the urinary epithelial cell layer, and orthogonal orientation to stratify the tumor into low-risk or high-risk recurrent tumors.
Clinical pathology features the transitional cell carcinoma of the bladder is divided into two groups: non-muscle invasive bladder cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC). Of these, MIBC is the leading cause of cancer-specific death in patients with bladder cancer. Although NMIBC is better survivable than MIBC and other malignancies, 30% -50% of NMIBC patients will experience relapse after their treatment, with approximately 10% -20% of relapses progressing to MIBC. Therefore, reducing the chances of recurrence and progression of bladder cancer has always been a major challenge for patients and physicians.
The current diagnosis of bladder cancer includes cystoscopy, urinalysis, color ultrasonography, CT nuclear magnetism, etc., of which the most common method is cystoscopy. Cystoscopy is an effective but invasive tool for detecting bladder cancer, has low sensitivity to carcinoma in situ (Tis), and is likely to be missed because its accuracy depends on the skill of the operator, and is more difficult to diagnose, especially in the case of recurrence. The sensitivity and specificity of cystoscopes are 62% -84% and 43% -98%, respectively, and depend on the type, stage and grade of the tumor. In addition, since cystoscopy is an invasive examination method, pain in urination (50%), frequency of urination (37%), hematuria (19%) and infection (3%) may frequently occur after examination, which may have adverse effects on the mind and body of the patient.
A noninvasive diagnosis method of urine cytology is utilized, a cytology technology is mainly adopted to detect the fallen tumor cells in urine, the sensitivity of the method is different from 28% to 100%, and the median is 44%. The sensitivity to high-grade tumors is high, and the sensitivity to low-grade tumors is only 4% -31%. Cytology is commonly used as an aid to cystoscopy. It therefore tends to facilitate the detection of high-grade diseases, the sensitivity of which depends on the experience of the cytopathologist. It is generally positive in the detection of high-grade diseases, but has limited use in the detection of low-grade diseases. When cystoscopy is negative and urine cytology is positive, further diagnosis is usually required by urinary tract imaging (such as CT urography, MR urography or intravenous pyelography) and ureteroscopy to directly display or detect the form of bladder cancer markers.
The bladder cancer markers are mostly distributed on the surface of urinary epithelial cells or in urine, and the risk of cancer of a patient is predicted by detecting the corresponding markers, so that the method has important significance in the processes of medical basic research and clinical research.
Urinary bladder cancer antigen (UBC), a novel bladder tumor marker, is essentially cytokeratin fragments 8 and 18 of bladder tumor origin. Cytokeratins (CKs) are a multigenic family of proteins that form in vivo water-insoluble intermediate fragments that are epithelial-derived cell-specific. From different epithelial tissues, there are 20 different CKs, further classified into type 1 (CK9-20) and type 2 (CK 1-8). Cytokeratins are markers of epithelial differentiation and a cell type can be identified by the expression of a specific cytokeratin. Specific cytokeratin fragments of normal urothelium origin and urothelial tumor origin exist in urine, and thus can be used as potential markers of bladder cancer. The learners use a qualitative UBC test method, and the method of calculating the area under the curve (AUC) and the like by the method of drawing an operation characteristic (ROC) curve and the like of a subject through clinical detection is used for analyzing the diagnosis accuracy of the UBC, and the overall sensitivity and specificity of the UBC also reach 61.3 percent and 77.3 percent respectively. Is the marker with the highest sensitivity for detecting bladder cancer antigen in urine at present.
Tumor targeting peptides (THPs) refer to polypeptides capable of specifically binding to tumor cells. Researches show that in the process of generating and developing tumors, the expression profile of cell surface protein genes has specific molecular expression change, and a group of codes of specific cancer types are formed, so that the genes become targets for early eliminating or diagnosing the tumors. The currently discovered tumor targeting peptides are usually active peptides with small molecular weight consisting of 5-31 amino acids. Compared with other antibodies, the small molecule polypeptide overcomes the problem that the antibodies have heterology; the molecular weight is small, the biological barrier is easy to pass through, the tissue can be effectively permeated, the affinity is high, and the efficient concentration of the ligand is ensured; easy chemical synthesis, low cost, automatic design, ensured physical, chemical and biological properties, and carrying fluorescent dye or medicine for targeted optical imaging and treatment. In the last decade, tumor targeting peptides have become effective targeting vehicles for anticancer agents and imaging agents for tumor regions.
Phage Display Technology (PDT), originally discovered by Smith, has now become a powerful tool for discovering new functional polypeptides and altering the properties of existing polypeptides, and has become a popular tool in cell biology and protein engineering. The PDT basic principle is to insert the gene of the foreign protein or polypeptide into the proper position of the structural gene of the coat protein of the phage, to fuse the two genes and express the fused genes on the surface of the phage, so that the displayed foreign protein or polypeptide not only keeps relatively independent spatial structure and biological activity, but also does not affect the infection capacity of the recombinant phage to host bacteria, thereby establishing the relationship between phenotype and genotype. It has the advantages of simple and convenient, high-efficiency and large-flux screening, can be cloned by phage combined with low-expression specific molecules through host bacterium amplification, and has been widely applied to screening and research and development of anti-tumor drugs, tumor diagnosis markers and the like. In recent years, in the research of screening tumor-targeted short peptides such as lung cancer, gastric cancer, liver cancer, colon cancer, prostate cancer and the like by applying a phage display technology, the research of tumor-specific binding peptides obtains a plurality of achievements. Therefore, the method for screening the short peptide by using the phage display technology becomes an effective tool for researching the binding site of the interaction between macromolecules and searching ligand molecules with high affinity and bioactivity, and researching and developing vaccines and diagnostic reagents.
Disclosure of Invention
The purpose of the invention is: the polypeptide molecule can be applied to a targeting molecular probe on one hand, and is expected to be used for targeted delivery of drugs by coupling corresponding drugs, so that the toxic and side effects of chemotherapeutic drugs on normal tissues or cells of a patient are effectively improved; on the other hand, after the tumor specific binding peptide is subjected to molecular marking, the early diagnosis and the prognosis detection of tumor markers in body fluid can be realized through a series of sensitive detection means. Lays a foundation for the development of human bladder cancer in-vitro noninvasive diagnosis (in urine) reagents and targeted therapy or imaging preparations.
The technical scheme of the invention is as follows: the human bladder cancer specific antigen binding peptide consists of 12 amino acids, the amino acid sequence is MPMFKHRMFHTH, wherein M is methionine residue, P is proline residue, F is phenylalanine residue, K is lysine residue, H is histidine residue, R is arginine residue, and T is threonine residue. Has a molecular weight of 2024.0, and can specifically bind to human urinary bladder cancer antigen (UBC).
Has a molecular structure of
The invention has the beneficial effects that:
(1) the polypeptide fragment can be specifically combined with urinary bladder cancer antigen (UBC), so that the polypeptide fragment and the derivative thereof have important application values in early diagnosis, screening and targeted therapy of bladder cancer tumors.
(2) Compared with the traditional screening method, the method has the advantages of simple and convenient operation by applying the phage display technology, easy realization of large-scale production, and laying a foundation for targeted development and targeted drug selection due to the advantages of small relative molecular weight, weak immunogenicity, high activity and the like.
Drawings
FIG. 1 is a diagram of the structure of a specific antigen-binding peptide molecule of the present invention;
FIG. 2 is a mass spectrometric identification of a specific antigen-binding peptide molecule of the invention;
FIG. 3 is a HPLC purity profile of a specific antigen-binding peptide of the present invention;
FIG. 4 is a specific antigen binding peptide affinity assay of the invention; wherein, controlgroup is blank group, detelmnatlongroup is determination group;
FIG. 5 is an affinity calculation experiment for a specific antigen-binding peptide of the present invention.
Detailed Description
Example 1
1. Screening of human bladder cancer specific antigen-binding peptides
By using a phage display technology, urinary bladder cancer antigen (UBC) is used as a substrate for coating, phage dodecapeptide library display screening is carried out, four rounds of incremental pressure screening are carried out, and finally, plaques are randomly picked for sequencing to obtain the human bladder cancer specific antigen binding peptide with the sequence of MPMFKHRMFHTH.
2. Preparation of human bladder cancer specific antigen binding peptide
The obtained human bladder cancer specific antigen-binding peptide sequence was synthesized by Shanghai Qiangyao Biotech Co., Ltd. The company identifies the synthesized target polypeptide by a mass spectrometry detection method and an HPLC detection method. The mass spectrum (fig. 2) shows that the molecular weight of the specific antigen-binding peptide is 2268.77, consistent with the theoretical molecular weight; HPLC detection in the figure (fig. 3) shows that the specifically synthesized antigen-binding peptide is 96.81% pure.
3. Biological identification of human bladder cancer specific antigen binding peptides
3.1 enzyme-linked immunosorbent assay (ELISA) for identifying specificity to UBC
With 150. mu.l of 100. mu.g/ml UBC molecules (dissolved in 0.1M pH 8.6 NaHCO)3Middle) three wells of ELISA plate were coated overnight at 4 ℃ in a sealed wet box. Each well was filled with 10mg/ml trehalose blocking solution. Adding blocking liquid into the non-coated holes beside the clone to be identified, and blocking all the blocking plates at 4 DEG CFor 1 hour. After removing the blocking solution, wash the plate 6 times with 1 × TBS/Tween solution, the concentration of Tween solution should be 1% the same as the concentration used in the washing step. In separate blocking plates 200. mu.l TBS/Tween were added per well and 10. mu.l of virions (phage solution) per well. Phage are added to the plate coated with the target molecule. Shaking at room temperature for 1 hour. Murine anti-M13 antibody was diluted 1:5,000 in TBS. Add 200. mu.l of diluted antibody to each well and shake for 1 hour at room temperature. HRP-labeled rabbit anti-mouse antibody was diluted 1:5,000 in TBS. Mu.l of diluted antibody was added to each well and incubated at 37 ℃ for 1 hour. Mu.l of TMB solution was added to each well and allowed to react at room temperature for 30min for color development. The color reaction was stopped by adding 2M sulfuric acid. The absorbance values (Abs) at 405nm were recorded by the microplate reader and the average values were calculated (fig. 4). The experimental data show that the screened human bladder cancer specific antigen-binding peptide can specifically adsorb UBC in comparison with a control group, and the difference is obvious in comparison with the control group, so that the human bladder cancer specific antigen-binding peptide is proved to have the specificity of adsorbing UBC.
3.2 determination of affinity constant of human bladder cancer-specific antigen-binding peptide for UBC.
In order to observe the affinity constant of the human bladder cancer specific antigen binding peptide to UBC, the invention adopts a biomembrane interference experiment method (BLI) to measure the affinity constant between the human bladder cancer specific antigen binding peptide and UBC protein. Affinity constant measurements were performed on 5 concentration gradients (100. mu.g/ml, 50. mu.g/ml, 25. mu.g/ml, 12.5. mu.g/ml, 6.25. mu.g/ml) of human bladder cancer-specific antigen-binding peptide, and the average value was calculated (FIG. 5). Calculating to obtain average R2＝0.975098，KD(M)＝2.18×10-7To within the reference value (10)-6<KD<10-11) As expected.
Sequence listing
<110> Changchun university of science and technology
<120> a human bladder cancer antigen specific binding peptide
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 12
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<220>
<221> BINDING
<222> (1)..(1)
<223> design according to the binding ability to the target protein
<400> 1
Met Pro Met Pro Leu His Ala Met Pro His Thr His
1 5 10
Claims (1)
1. A human bladder cancer specific antigen binding peptide, which is characterized in that: the human bladder cancer specific antigen binding peptide consists of 12 amino acids, the amino acid sequence is MPMFKHRMFHTH, wherein M is methionine residue, P is proline residue, F is phenylalanine residue, K is lysine residue, H is histidine residue, R is arginine residue, and T is threonine residue. Has a molecular weight of 2024.0, and can specifically bind to bladder cancer antigen in human urine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010560431.9A CN113372415A (en) | 2020-06-18 | 2020-06-18 | Human bladder cancer specific antigen binding peptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010560431.9A CN113372415A (en) | 2020-06-18 | 2020-06-18 | Human bladder cancer specific antigen binding peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113372415A true CN113372415A (en) | 2021-09-10 |
Family
ID=77569543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010560431.9A Pending CN113372415A (en) | 2020-06-18 | 2020-06-18 | Human bladder cancer specific antigen binding peptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113372415A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080042539A (en) * | 2006-11-10 | 2008-05-15 | 경북대학교 산학협력단 | Bladder tumor-targeting peptides and uses thereof |
| US20140219956A1 (en) * | 2013-02-07 | 2014-08-07 | Immunomedics, Inc. | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| CN104593359A (en) * | 2014-12-26 | 2015-05-06 | 山西医科大学第一医院 | Bladder transitional cell carcinoma cell line BIU87 specifically-bound polypeptide and application thereof |
| CN109563128A (en) * | 2016-08-16 | 2019-04-02 | 国立研究开发法人产业技术总合研究所 | Malignant tumour targeting peptides |
| CN112521455A (en) * | 2020-12-08 | 2021-03-19 | 长春理工大学 | Polypeptide for detecting bladder cancer antigen protein specificity and application thereof |
| CN113372414A (en) * | 2020-06-15 | 2021-09-10 | 长春理工大学 | Fluorescent probe for detecting ochratoxin A and preparation method thereof |
-
2020
- 2020-06-18 CN CN202010560431.9A patent/CN113372415A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080042539A (en) * | 2006-11-10 | 2008-05-15 | 경북대학교 산학협력단 | Bladder tumor-targeting peptides and uses thereof |
| US20140219956A1 (en) * | 2013-02-07 | 2014-08-07 | Immunomedics, Inc. | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| CN104593359A (en) * | 2014-12-26 | 2015-05-06 | 山西医科大学第一医院 | Bladder transitional cell carcinoma cell line BIU87 specifically-bound polypeptide and application thereof |
| CN109563128A (en) * | 2016-08-16 | 2019-04-02 | 国立研究开发法人产业技术总合研究所 | Malignant tumour targeting peptides |
| CN113372414A (en) * | 2020-06-15 | 2021-09-10 | 长春理工大学 | Fluorescent probe for detecting ochratoxin A and preparation method thereof |
| CN112521455A (en) * | 2020-12-08 | 2021-03-19 | 长春理工大学 | Polypeptide for detecting bladder cancer antigen protein specificity and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| ARISGIANNOPOULOS等: "COMPARATIVE EVALUATION OF THE DIAGNOSTIC PERFORMANCE OF THE BTA STAT TEST, NMP22 AND URINARY BLADDER CANCER ANTIGEN FOR PRIMARY AND RECURRENT BLADDER TUMORS", 《THE JOURNAL OF UROLOGY》 * |
| SHUHEISUMI等: "Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder", 《CLINICA CHIMICA ACTA》 * |
| 杨超铭等: "利用噬菌体展示技术筛选膀胱癌细胞标志物特异性配体", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 * |
| 罗俊茜等: "利用体内噬菌体展示技术筛选膀胱癌特异性结合肽", 《中国免疫学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Anorma et al. | Surveillance of cancer stem cell plasticity using an isoform-selective fluorescent probe for aldehyde dehydrogenase 1A1 | |
| CN107459559B (en) | Tumor immunotherapy prediction biomarker PD-L1 targeting polypeptide and application thereof | |
| WO2010125566A2 (en) | Markers for cancer detection | |
| CN108872438B (en) | Rapid detection kit for lung cancer marker GK5 in exosome | |
| KR101698654B1 (en) | DNA aptamer specifically binding to EN2 (Engrailed-2) and use thereof | |
| CN101492505B (en) | Specific combined polypeptide for lung cancer, preparation and uses thereof | |
| WO2019154103A1 (en) | Novel polypeptide for tumor targeting and application thereof | |
| CN110330551B (en) | Pancreatic cancer specific binding peptide and preparation method and application thereof | |
| CN109467588B (en) | Polypeptide of targeted human N-cadherin protein and application thereof | |
| CN112521455B (en) | Polypeptide for detecting bladder cancer antigen protein specificity and application thereof | |
| AU2009313167B2 (en) | Use of EEF1A as biomarker for screening of MetAP2 inhibitors | |
| JP5347028B2 (en) | Use of EEF1A as a biomarker and method for screening for MetAP2 inhibitors | |
| CN109628455B (en) | Aptamer for detecting human colon cancer and application of aptamer in preparation of detection preparation | |
| CN113372415A (en) | Human bladder cancer specific antigen binding peptide | |
| Huang et al. | Near-infrared targeted EGFR fluorescent probe for tumor imaging and diagnosis | |
| Bloch et al. | The effect of linker type and recognition peptide conjugation chemistry on tissue affinity and cytotoxicity of charged polyacrylamide | |
| CN112083160A (en) | Preparation and application of quantum dot immunofluorescence kit for detecting cervical cancer | |
| CN111944820A (en) | Rapid screening of tissue sample of bladder cancer aptamer and application of rapid screening in detection preparation | |
| US9012656B2 (en) | Oligothiophene derivate as molecular probes | |
| KR101757176B1 (en) | Peptide probe for detecting colon cancer | |
| CN110950931A (en) | Polypeptide for specifically targeting triple negative breast cancer stem cells and application thereof | |
| CN103788181B (en) | Lung carcinoma cell specific adhesion small peptide and application thereof | |
| CN111018951B (en) | Polypeptide targeting triple negative breast cancer cells and application thereof | |
| US20150004621A1 (en) | Biological marker for early cancer detection and methods for cancer detection (bf819) | |
| CN112250733B (en) | Fluorescent molecular probe for targeted labeling of non-small cell lung cancer and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210910 |